Light Chain Cardiac Amyloidosis With Skeletal Muscle Weakness.

Elyn Montgomery, Natasha Gorrie, Georgia McCaughan, James Nadel, Karan Shahi, N K Bart, Antonia S Carroll

Abstract readCase Reports

In one paragraph

Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Elyn MontgomeryVictor Chang Cardiac Research Institute, Darlinghurst, New South Wales, Australia; St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia; Faculty of Health, University of Technology Sydney, Ultimo, New South Wales, Australia. Electronic address: Elyn.Montgomery@svha.org.au.

Natasha GorrieVictor Chang Cardiac Research Institute, Darlinghurst, New South Wales, Australia; St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia; Faculty of Medicine and Health, School of Clinical Medicine, University of New South Wales, Kensington, New South Wales, Australia.

Georgia McCaughanSt Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia; Faculty of Medicine and Health, School of Clinical Medicine, University of New South Wales, Kensington, New South Wales, Australia; Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.

James NadelCardiology Department, St Vincent's Hospital, Darlinghurst, New South Wales, Australia; Heart Research Institute, Newtown, New South Wales, Australia; School of Medicine, University of Notre Dame, Sydney, New South Wales, Australia.

Karan ShahiVictor Chang Cardiac Research Institute, Darlinghurst, New South Wales, Australia; St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia; School of Medicine, University of Notre Dame, Sydney, New South Wales, Australia.

N K BartVictor Chang Cardiac Research Institute, Darlinghurst, New South Wales, Australia; Faculty of Medicine and Health, School of Clinical Medicine, University of New South Wales, Kensington, New South Wales, Australia; Cardiology Department, St Vincent's Hospital, Darlinghurst, New South Wales, Australia; School of Medicine, University of Notre Dame, Sydney, New South Wales, Australia.

Antonia S CarrollSt Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia; Faculty of Medicine and Health, Brain and Mind Centre, Sydney University, Camperdown, New South Wales, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAmyloid light chain (AL) amyloidosis can manifest with heterogeneous, multisystem features. Cardiac involvement is common and drives prognosis. CASE SUMMARY: A 54-year-old man presented with proximal muscle weakness, autonomic and gastrointestinal symptoms, and exertional intolerance. Skeletal muscle imaging suggested myositis. Cardiac evaluation revealed conduction disease, and echocardiography was consistent with infiltrative cardiomyopathy. Fluorodeoxyglucose positron emission tomography demonstrated myocardial uptake. Targeted biopsies confirmed AL amyloidosis. Plasma cell-directed therapy achieved a partial hematologic response. Given the t(11;14), the patient began a trial of a novel BCL-2 inhibitor. DISCUSSION: Fluorodeoxyglucose-avid myocardium is described in amyloidosis but is not diagnostic. When a concurrent plasma cell clone or other red flags are present, a high index of suspicion should be maintained for AL amyloidosis. TAKE-HOME MESSAGES: A high index of suspicion should be maintained for cardiac AL amyloidosis in patients with atypical cardiac findings. Unexplained muscle weakness should prompt evaluation for systemic AL amyloidosis even with subtle cardiac findings.

Indexed as

cardiomyopathydiastolic heart failureimaging

Identifiers

PMID42782030

DOI10.1016/j.jaccas.2026.108673

PMCPMC13616555

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.